NIAID RSVF2-5
NIAID RSVF2-5 is a human monoclonal antibody fragment. NIAID RSVF2-5 binds to conserved, distinct conformational epitopes on RSV fusion glycoprotein, and shows activity against RSV subgroup A and B strains. NIAID RSVF2-5 reduces pulmonary and lung viral titers in RSV-infected rodents. NIAID RSVF2-5 can be used for the research of respiratory syncytial virus infection.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Species Reactivity
Human
In Vitro
NIAID RSVF2-5 neutralizes RSV Tracy (subgroup A) and RSV 18537 (subgroup B) in HEp-2 cells with IC50 values of 3.6 μg/mL and 1.8 μg/mL, respectively[2].
NIAID RSVF2-5 neutralizes RSV A2 (subgroup A) in HEp-2 cells with an IC60 of 0.07 μg/mL[2].
NIAID RSVF2-5 binds to purified RSV A2 strain gF protein with a KD of 4.9 × 10-10 M[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
NIAID RSVF2-5 (5-15 mg/kg; i.p. or i.m.; single dose; 1 day prior to challenge) significantly reduces lung viral titers in RSV-challenged cotton rats when administered prophylactically[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice (female, 42 weeks old, average weight 25 g) intranasally inoculated with RSV strain A2[1]
-
Dosage:0.0039; 0.0156; 0.0625; 0.25; 1.0; 4.0 mg/kg
-
Administration:i.n.; single dose; on day 4 after infection
-
Result:Achieved a 2000-fold reduction in mean lung RSV titer (to 1.9 log10 pfu/g) with virus detected in only 1 of 6 animals at 4.0 mg/kg; reduced mean nasal turbinate RSV titer to 3.2 log10 pfu/g at 4.0 mg/kg.
Reduced mean lung RSV titer to 3.3 log10 pfu/g and mean nasal turbinate RSV titer to 3.8 log10 pfu/g at 1.0 mg/kg.
Reduced mean lung RSV titer to 4.3 log10 pfu/g and mean nasal turbinate RSV titer to 4.4 log10 pfu/g at 0.25 mg/kg.
Reduced mean lung RSV titer to 4.0 log10 pfu/g and mean nasal turbinate RSV titer to 4.2 log10 pfu/g at 0.0625 mg/kg.
Showed no significant reduction in lung or nasal turbinate RSV titers relative to untreated controls at 0.0156 mg/kg and 0.0039 mg/kg.
-
Animal Model:Sigmodon hispidis (60-125 g) intranasally administered with RSV[2]
-
Dosage:15; 5 mg/kg (i.p.); 12 mg/kg (i.m.)
-
Administration:i.p. or i.m.; single dose 1 day prior to challenge
-
Result:Showed no significant reduction in nasal titer at 15 mg/kg (i.p.), with nasal titer measured at 4.95 log10 total PFU.
Reduced lung titer by 0.93 log10 (9-fold) from control at 15 mg/kg (i.p.), with lung titer at 3.96 log10 PFU/g.
Showed no significant reduction in nasal titer at 5 mg/kg (i.p.), with nasal titer measured at 4.90 log10 total PFU.
Reduced lung titer by 0.59 log10 from control at 5 mg/kg (i.p.), with lung titer at 4.3 log10 PFU/g.
Showed no significant reduction in nasal titer at 12 mg/kg (i.m.), with nasal titer measured at 4.45 log10 total PFU.
Reduced lung titer by 1.21 log10 (17-fold) from control at 12 mg/kg (i.m.), with lung titer at 3.7 log10 PFU/g.
Accession
A0A0X8XRK2
Target
RSV-F
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Crowe JE Jr, et al. Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo. J Infect Dis. 1998;177(4):1073-1076. [Content Brief]
[2]. Zeitlin L, et al. Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model. MAbs. 2013;5(2):263-269. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
NIAID RSVF2-5 Related Classifications
HY-P992423 Related Classifications
Powered by Bioz